ExThera Medical Corporation (ExThera) is developing revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections.
ExThera has developed a first-of-its-kind blood filter designed to reduce pathogens during bloodstream infections. Harmful substances are captured and adsorbed onto the device’s proprietary surface. Their concentration in the bloodstream is thereby reduced without adding anything to the treated blood, which is then returned to the patient with blood cells intact.
The company is focused on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations.
ExThera’s proprietary Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is a first-of-its kind, CE Marked, technology designed to reduce bloodborne pathogens during bloodstream infections. Validated in preclinical studies and in a clinical trial in Europe, the device promises to address significant unmet needs for immediate treatment, even before the pathogen is identified.
Steven Opal, M.D. (Brown University) editorial in Critical Care highlights the need for non-antibiotic alternatives for treating pan-resistant bloodstream infections, referencing our work with Seraph.
ExThera Medical has completed a multi-center, non-randomized European trial for the Seraph® Microbind® Affinity Blood Filter (Seraph).